Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

510(k) clearance for Picker's ACQPLAN :

This article was originally published in Clinica

Executive Summary

The FDA has cleared Picker International's ACQPLAN three dimensional radiation therapy planning (RTP) system for marketing in the US. The device calculates treatment dose in monitor units and can also be used with the company's ACQSIM CT simulator, eliminating the need to transfer CT simulation images to remote RTP workstations. With the integrated ACQPLAN/ACQSIM system, the patient only needs to be scanned for around two minutes, long enough to acquire basic datasets. The whole simulation and three-dimensional RTP process is then carried out using this "virtual" CT data. This method increases patient's comfort as well as CT scanner throughput hence reduces costs, said Picker.

You may also be interested in...



Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

US FDA Requests Frequent Updates On Supply Chain Disruptions In COVID-19 Era

Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.

Topics

UsernamePublicRestriction

Register

MT082070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel